Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Documented sequence: Lys-Glu-Asp-Gly
Source: PMID22117547
Sequence named in the paper; the fluorescent experimental peptide does not certify a commercial vial.
Mechanism
Tetrapeptide described as Lys-Glu-Asp-Gly in a nuclear-penetration study; that description does not validate testicular tropism.
Evidence and critical reading
Reported scientific and empirical uses
Fertility and reproduction
Endocrine/reproductive promotion; do not turn the name Testagen into evidence of testosterone elevation.
Human evidence
The primary study used labeled peptides in HeLa cells/DNA interaction. The 2025 copper-corrosion paper is not counted as therapeutic evidence.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
The primary study used labeled peptides in HeLa cells/DNA interaction. The 2025 copper-corrosion paper is not counted as therapeutic evidence.
The primary study used labeled peptides in HeLa cells/DNA interaction. The 2025 copper-corrosion paper is not counted as therapeutic evidence.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
No clinical regimen or human hormonal benefit was verified. Cell uptake does not define reproductive/genomic safety.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID22117547 · Cell experiment
HeLa cells/DNA assays.
Fluorescent peptides, in vitro.
Nuclear penetration/DNA interaction.
Labeling/culture are not patient-vial distribution or benefit.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Testagen · 1 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT02733133 · Product Transference Study of Testagen™ TDS®-TestosteroneRegistry status: Not yet recruitingLast update posted: May 27, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID22117547
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF.
October 16, 2026
- SEARCH-PUBMED-testagen
PubMed/MED targeted search: TITLE_ABS:testagen
October 16, 2026